Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 90, Issue -, Pages 876-888Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2014.12.014
Keywords
Organoselenium compound; X-ray crystallography; DFT studies; DNA binding; pBR322 hydrolytic cleavage; GPx activity
Categories
Funding
- DST, University of Kashmir
- DST-PURSE [SR/S9/Z-23/2008/12(C)]
- DST-FIST programme [CSI-234/2011]
- DRS-I (SAP) from UGC, New Delhi, India [F.540/1/DRS/2009/(SAP-I)]
- CSIR-SRF (SRF scheme), New Delhi [2013: 9/112(503) 2K13-EMR-I]
Ask authors/readers for more resources
New pharmacophore organoselenium compound (1) was designed, synthesized and characterized by various spectroscopic methods (IR, ESI-MS, H-1, C-13 and Se-77 NMR) and further confirmed by X-ray crystallography. Compound 1 consists of two 3,5-bis(trifluoromethyl)phenyl units which are connected to the selenium atom via the organometallic C-Se bond. In vitro DNA binding studies of 1 was investigated by absorption and emission titration methods which revealed that I recognizes the minor groove of DNA in accordance with molecular docking studies with the DNA duplex. Gel electrophoretic assay demonstrates the ability of 1 to cleave pBR322 DNA through hydrolytic process which was further validated by T4 religation assay. To understand the drug-protein interaction of which ultimate molecular target was DNA, the affinity of 1 towards HSA was also investigated by the spectroscopic and molecular modeling techniques which showed hydrophobic interaction in the subdomain HA of HSA. Furthermore, the intracellular localization of 1 was evidenced by cell imaging studies using HeLa cells. (C) 2014 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available